PATH Study: Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia
Enrolling By Invitation
18 years - 99 years
All
Phase
N/A
16 participants needed
1 Location
Brief description of study
This research study is to determine the safety and tolerability of pomalidomide for the treatment of HHT; to determine if pomalidomide treatment improves quality of life in HHT; to determine whether a continued response to pomalidomide is evident 12 weeks after treatment discontinuation; to develop a biorepository for future studies to define biomarkers predictive of pomalidomide response and allow investigations into the biology of HHT and mechanisms of pomalidomide
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Hereditary Hemorrhagic Telangiectasia
-
Age: 18 years - 99 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 842685
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
